Zhu Longtu, Li Xiaoye, Lu Qingsheng
Division of Vascular Surgery, Department of General Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Front Cardiovasc Med. 2023 Feb 24;10:1034354. doi: 10.3389/fcvm.2023.1034354. eCollection 2023.
Thoracic endovascular aortic repair, initially intended for thoracic aortic disease treatment, has extended its application to the proximal zone of the aorta. However, the safety and surgical outcomes of extending the proximal landing zone into the ascending aorta (zone 0) in selected cases remain unknown. Thus, we performed a systematic review and meta-analysis of zone 0 thoracic endovascular aortic repair (TEVAR) to obtain a deeper understanding of its safety, outcomes, and trends over time.
A literature search was performed using PubMed, EMBASE, and Web of Science databases in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines, from January, 1997 to January, 2022. Only studies involving zone 0 TEVAR were included. The retrieved data from the eligible studies included basic study characteristics, 30-day/in-hospital mortality rate, indications, comorbidities, stent grafts, techniques, and complications. Summary effect measures of the primary outcomes were obtained by logarithmically pooling the data with an inverse variance-weighted fixed-effects model.
Fifty-three studies with 1,013 patients were eligible for analysis. The pooled 30-day/in-hospital mortality rate of zone 0 TEVAR was 7.49%. The rates of post-operative stroke, type Ia endoleak, retrograde type A aortic dissection, and spinal cord ischemia were 8.95, 9.01, 5.72, and 4.12%, respectively.
Although many novel stent grafts and techniques targeting zone 0 TEVAR are being investigated, a consensus on technique and device selection in zone 0 TEVAR is yet to be established in current practice. Furthermore, the post-operative stroke rate is relatively high, while other complication rates and perioperative death rate are comparable to those of TEVAR for other aortic zones.
胸主动脉腔内修复术最初旨在治疗胸主动脉疾病,现已将其应用扩展至主动脉近端区域。然而,在特定病例中将近端锚定区扩展至升主动脉(0区)的安全性和手术效果仍不明确。因此,我们对0区胸主动脉腔内修复术(TEVAR)进行了系统评价和荟萃分析,以更深入地了解其安全性、效果及随时间的变化趋势。
按照系统评价和荟萃分析的首选报告项目指南,于1997年1月至2022年1月期间使用PubMed、EMBASE和Web of Science数据库进行文献检索。仅纳入涉及0区TEVAR的研究。从符合条件的研究中检索的数据包括基础研究特征、30天/住院死亡率、适应证、合并症、支架移植物、技术及并发症。主要结局的汇总效应量通过采用逆方差加权固定效应模型对数据进行对数合并获得。
53项研究共1013例患者符合分析条件。0区TEVAR的汇总30天/住院死亡率为7.49%。术后卒中、Ia型内漏、逆行性A型主动脉夹层和脊髓缺血的发生率分别为8.95%、9.01%、5.72%和4.12%。
尽管针对0区TEVAR正在研究许多新型支架移植物和技术,但目前实践中尚未就0区TEVAR的技术和器械选择达成共识。此外,术后卒中发生率相对较高,而其他并发症发生率和围手术期死亡率与其他主动脉区域的TEVAR相当。